Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMKETFV)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
67200-34-4; SMER 3; 9H-Indeno[1,2-e][1,2,5]oxadiazolo[3,4-b]pyrazin-9-one; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one; SMER-3; C11H4N4O2; LSM-42773; 9H-Indeno-[1,2-e]-[1,2,5]-oxadiazolo-[3,4-b]-pyrazin-9-one; indeno[2,3-b]1,2,5-oxadiazolo[3,4-e]pyrazin-5-one; 2-Oxa-1,3,4,10-tetraaza-cyclopenta[b]fluoren-9-one; SMER3(SMER 3); Oprea1_175199; Oprea1_783821; SCHEMBL7984580; CHEMBL3589013; ZINC27763; AOB5567; DTXSID40340952; CHEBI:131171; BDBM188214; HMS1607O01; BCP14360; 2188AH; MFCD00451458; SBB000632; STK120842; SMER3, >=98% (HPLC); AKOS000479457; MCULE-1070513713; AS-55891; ST000573; DB-073845; FT-0701471; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one,; US9073941, 28; US9073941, 30; SR-01000388225; SR-01000388225-1; Q27224946; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one #
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Lung
Lung adenocarcinoma
Pancreas
Pancreatic carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
